Lipocine Inc. · NASDAQ:LPCN
Lipocine — Investor Presentation (March 2026)
6 slides from Lipocine's investor presentation, March 2026
Slide 1: LPCN 2401 Obesity Management – adjunct to GLP-1
LPCN 2401 Obesity Management – adjunct to GLP-1
Slide 2: Unprecedented Demand and Usage of GLP-1 Receptor Agonists
Unprecedented Demand and Usage of GLP-1 Receptor Agonists 1-3 GLP-1 market trending toward oral once daily dosing Semaglutide: $30 billion sales in the US in 20244 ✓ T2DM Tirzepatide: $14 billion sales in the US in 20245 ✓ Weight management FDA approved ✓ Cardiovascular disease indications ✓ Chronic
Slide 3: Drawbacks of Approved GLP-1 Receptor Agonists
Drawbacks of Approved GLP-1 Receptor Agonists Rapid loss of lean mass and functionality in elderly GLP-1 users Low Quality Weight Loss1 Lean Mass Loss1 Functionality Loss1 Fracture Risk2,3 Weight Loss Lean mass Loss Weight(kg) Loss Fatloss Fat Loss(%) Lean Mass (%) Loss 0 3 Semaglutide % Subjects wi
Slide 4: Once Daily Oral as An Adjunct to GLP-1 Treatment
LPCN 2401 Once Daily Oral as An Adjunct to GLP-1 Treatment Proven potential to improve body composition - quality weight loss with quality fat loss Product Candidate Attributes Proprietary androgen receptor agonist, testosterone ester(s), targeted for once-a-day treatment - “LPCN 2401” • Androgen re
Slide 5: LPCN 2401 – Clinical Data Show Significant Improvement in Body Composition
LPCN 2401 – Clinical Data Show Significant Improvement in Body Composition Phase 2 results demonstrate increased lean mass and decreased fat mass at Week 20 Lean Mass Fat Mass Lean Mass (kg) Appendicular Lean Mass (kg) Total Fat Mass Trunk Fat Mass 2.5 (kg) (kg) 2 1 2 * * 0.9 1.9 1.5 1.2 1.6 1 * * 0
Slide 6: Novel Oral Treatment for Obesity Management
LPCN 2401 Novel Oral Treatment for Obesity Management Target benefits to improve weight loss and functionality Quality Weight Loss Maintain Weight Loss Preserve lean mass Primarily fat loss Minimize fat regain Minimize weight regain Attenuate functionality loss Maintain/improve functionality Amplify